HETERO LABS LIMITED
Location
Telangana
Founded
1989-03-10
Website
Risk Signals
263 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about HETERO LABS LIMITED
Live alerts from global media, monitored by Business Radar
2023-04-24 (expresspharma.in)
Sun Pharma, Hetero recall drugs in US
Sun Pharma is recalling a generic drug indicated to raise blood pressure in adults while Hetero Labs is recalling a drug used to treat certain stomach and oesophagus problems
Read more
2019-09-23 (outsourcing-pharma.com)
Torrent expands recall of losartan products, again
Torrent announces that it will recall batches of losartan tablets for the sixth time, after the detection of NMBA exceeding acceptable daily intake levels in latest recall.
Read more
2019-06-11 (miamiherald.com)
Torrent Pharmaceuticals recalls 5 lots of losartan potassium
Torrent Pharmaceuticals recalls five lots of heart and blood pressure medication losartan after finding “unexpected impurity” NMBA in the active ingredient made by Hetero Labs Limited.
Read more
2019-04-26 (fda.gov)
Teva Pharmaceuticals USA, Inc. Issues Voluntary Nationwide Recall of Losartan Potassium 25 mg and 100 mg Tablets USP, Sold Exclusively to Golden State Medical Supply |
Teva Pharmaceuticals USA, Inc. has initiated a voluntary recall in the United States, to the patient level, of 35 lots of bulk Losartan Potassium USP Tablets (6 lots of 25 mg strength and 29 lots of 100 mg strength).
Read more
2019-04-18 (fda.gov)
Updated: Torrent Pharmaceuticals Limited Expands Voluntary Nationwide Recall of Losartan Potassium Tablets, USP and Losartan Potassium/Hydrochlorothiazide Tablets, USP
Torrent Pharmaceuticals Limited is expanding its recall for Losartan Potassium Tablets USP and Losartan Potassium/hydrochlorothiazide tablets, USP, to the consumer level due to the detection of trace amounts of an unexpected impurity
Read more
2019-03-29 (theonlinecitizen.com)
HSA recalls three brands of Losartan medicines from Hetero Labs Ltd
The Health Sciences Authority (HSA) has recalled Hyperten Tablet, Losagen Tablet, and Losartas Tablet from Hetero Labs Ltd as they were found to contain trace amounts of a nitrosamine impurity, N-nitroso-N-methyl-4-aminobutyric acid (NMBA), which are above internationally acceptable levels.
Read more
2019-03-19 (nrc.nl)
Cancer-causing pollution in blood pressure medicine again
Contaminated medicines: The Inspectorate recalls contaminated losartan pills from 16,000 patients in the Netherlands. Last month it turned out that millions worldwide…
Read more
2019-03-04 (taipeitimes.com)
FDA recalls blood pressure drugs over cancer doubts
The Food and Drug Administration (FDA) has ordered that two generic blood pressure drugs be removed from shelves, after its US counterpart found new potentially carcinogenic impurities in them.
Read more
2019-03-01 (fda.gov)
Updated: Torrent Pharmaceuticals Limited Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP and Losartan Potassium /Hydrochlorothiazide Tablets, USP
Torrent Pharmaceuticals Limited is voluntarily recalling 60 lots of Losartan potassium tablets USP and 54 lots of Losartan potassium/ hydrochlorothiazide tablets, USP, to the consumer level due to the detection of trace amounts of an unexpected impurity found in an active pharmaceutical ingredient (
Read more